Home › Aradigm Co. (ARDM) Downgraded by Zacks Investment Research to "Sell"
 

Keywords :   


Aradigm Co. (ARDM) Downgraded by Zacks Investment Research to "Sell"

2015-12-15 02:20:08| Biotech - Topix.net

According to Zacks, "Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.

Tags: to research sell investment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.07Atlantic Tropical Weather Outlook
04.07Eastern North Pacific Tropical Weather Outlook
04.07Hurricane Beryl Graphics
04.07Hurricane Beryl Public Advisory Number 22A
04.07Summary for Hurricane Beryl (AT2/AL022024)
04.07Japan declares victory in 'war' on floppy disks
04.07'Airport parking firms left us out of pocket'
04.07Jeff Bezos to sell another $5bn of Amazon shares
More »